D Hahn

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial

Karolin Behringer, Helen Goergen, Felicitas Hitz et al. · The Lancet · 2014 · 178 citations

Hematological Malignancy, Lymphoid Neoplasia, Ghsg Hd13 +10

Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial

Heiner Zimmermann, Christian Koenecke, Martin Dreyling et al. · Leukemia · 2022 · 34 citations · Full text

Modified Risk-stratification, Rituximab Monotherapy, Solid Organ Transplantation +20

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial

Andreas Hüttmann, Jan Rekowski, Stefan Müller et al. · Annals of Hematology · 2019 · 27 citations

Lymphoid Neoplasia, Medicine, Pathology +3

Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry

Heiner Zimmermann, Mirko Nitsche, Christiane Pott et al. · Annals of Hematology · 2021 · 16 citations

Neuro-oncology, Radiation Oncology, Transplantation +13